
Keywords: خودکار ایمن; AEs; adverse events; AI; auto-immune; CPI; check-point inhibitor; CSF-1R; colony-stimulating factor-1 receptor; EMA; European Medicines Agency; FDA; food and drug administration; irAEs; immune-related adverse events; NSCLC; non-small cell lung cancer; OVs